Profile of Immunoglobulin G and IgM Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Top Cited Papers
Open Access
- 27 April 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 71 (16), 2255-2258
- https://doi.org/10.1093/cid/ciaa489
Abstract
We profiled the serological responses to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) nucleocapsid (N) protein and spike (S) glycoprotein. The majority of the patients developed robust antibody responses between 17 and 23 days after illness onset. Delayed, but stronger antibody responses were observed in critical patients.Keywords
Funding Information
- Shenzhen Key Laboratory of Biochip (ZDSYS201504301534057)
- Bill and Melinda Gates Foundation
This publication has 9 references indexed in Scilit:
- Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational studyThe Lancet Respiratory Medicine, 2020
- Pathological findings of COVID-19 associated with acute respiratory distress syndromeThe Lancet Respiratory Medicine, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routesEmerging Microbes & Infections, 2020
- Anti–spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infectionJCI Insight, 2019
- Kinetics of Serologic Responses to MERS Coronavirus Infection in Humans, South KoreaEmerging Infectious Diseases, 2015
- Viral etiology of community-acquired pneumonia among adolescents and adults with mild or moderate severity and its relation to age and severityBMC Infectious Diseases, 2015
- Longitudinal Profile of Immunoglobulin G (IgG), IgM, and IgA Antibodies against the Severe Acute Respiratory Syndrome (SARS) Coronavirus Nucleocapsid Protein in Patients with Pneumonia Due to the SARS CoronavirusClinical and Vaccine Immunology, 2004
- Profile of Specific Antibodies to the SARS-Associated CoronavirusNew England Journal of Medicine, 2003